Health
CSOFT’s health blog aims to provide insight into complex diseases, treatment options and regulatory developments, and other prevalent health issues people face today.
ImmunoGen Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, provided an update on the pivotal Phase 2 CADENZA study of pivekimab sunirine (pivekimab) in blastic plasmacytoid dendritic cell neoplasm...
FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that the U.S. Food and Drug Administration (FDA) has notified Curis that it may resume enrollment of additional patients in...
iCAD Customers in the U.S. and Europe Increasingly Adopting Company’s Full Suite of Breast AI Technologies via Subscription Model
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced that a growing number of hospitals and imaging centers in the U.S. and Europe are increasingly choosing to adopt iCAD’s Breast AI...
Journal of Pharmaceutical Analysis Articles Highlight the Potential of Nanotechnology to Detect Clinically Useful Biomolecules
The advent of nanotechnology has led to exciting innovations across all fields of healthcare. While drug delivery and disease treatment are the most discussed medical applications of nanotechnology, recent studies published in Volume 12 Issue 3 of Journal of...
Medical Patent Application Translations: Meeting International Language Requirements for Patent Applications
How can medical device patent application translations help companies maintain a competitive edge in global markets? While medical device patents help prevent other companies from importing, replicating, or using your device domestically, they need to be validated in...
Baxter Broadens Efforts to Increase Awareness, Education and Support of Kidney Health in Black Communities
Baxter International, Inc. (NYSE:BAX), a global medtech leader, announces the national expansion of its partnership with international not-for-profit organization The Links, Incorporated (The Links) to continue bringing awareness and resources for the disproportionate...
SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, announced results from a new preclinical in vitro study...
Todos Medical Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women
Todos Medical Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced that its Atlanta-area CLIA/CAP-certified clinical laboratory Provista Diagnostics, Inc. has initiated a MonkeyPox diagnostic case study series evaluating...
Teleflex to Expand Its Surgical Portfolio with Differentiated Stapling Technology for Bariatric Surgery Signs Definitive Agreement to Acquire Standard Bariatrics
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, announced it has entered into a definitive agreement to acquire Standard Bariatrics, Inc. which has commercialized an innovative powered stapling technology for bariatric surgery....
Sorrento Therapeutics Announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, An Oral Mpro Inhibitor for Phase I Trial In COVID-19 Patients
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced the NMPA clearance of a Phase I study of its oral main viral protease (Mpro) inhibitor, STI-1558, in subjects with COVID-19 in a MAD study in China. In a previously announced Australia Phase I study in...
Categories
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com